Icatibant Universal Farma (Icatibant)

Icatibant is used to target the bradykinin‑mediated pathway in hereditary angioedema.

• Hereditary angioedema (C1‑inhibitor deficiency): provides rapid reduction of swelling during acute attacks.
• Hereditary angioedema type I: helps control edema and improve patient comfort in acute episodes.
• Hereditary angioedema type II: facilitates faster resolution of swelling and airway protection during attacks.

• Icatibant selectively binds to and blocks the bradykinin B2 receptor on vascular endothelial cells. By preventing bradykinin from activating this receptor, the drug inhibits bradykinin‑induced vasodilation and increased vascular permeability, thereby reducing the fluid extravasation that causes the swelling characteristic of hereditary angioedema attacks.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the subcutaneous injection site.
• Redness or swelling at injection site: transient erythema and local edema.
• Headache or nausea: occasional mild systemic symptoms.

Serious or Rare Side Effects

• Anaphylactic reaction: rapid onset of hives, breathing difficulty, or hypotension.
• Paradoxical angioedema: worsening swelling despite therapy.
• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Urticaria or widespread rash: immune‑mediated skin reactions.
• Thrombocytopenia: rare decrease in platelet count.

Icatibant should be administered only under medical supervision with attention to the following precautions.

• Dose administration: follow the prescriber's exact instructions for subcutaneous injection.
• Renal impairment: monitor renal function and adjust use if necessary.
• Hepatic impairment: use with caution in patients with liver disease.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Concomitant ACE inhibitors: may increase bradykinin levels and heighten risk of angioedema.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other agents that influence bradykinin pathways.

Major Interactions (Avoid)

• ACE inhibitors: can elevate bradykinin levels and increase risk of angioedema.
• Neprilysin inhibitors: may potentiate bradykinin activity, heightening adverse reactions.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor blood pressure and electrolyte balance.
• Other antihypertensives: observe for additive hypotensive effects.
• Hormonal contraceptives or estrogen therapy: may modestly raise bradykinin, requiring vigilance for swelling.